SANUWAVE Health news

The company reported declining revenues (-3% YoY), compressed gross margins (-190 bps), and a swing from operating income to operating loss. System sales fell significantly due to CMS reimbursement challenges and competition from used equipment markets. The withdrawal of 2026 guidance and CEO acknowledgment of a 'challenging period' further indicate deteriorating business conditions, despite strong applicator unit volume growth.

Mixed results with modest revenue growth (3.1% YoY) offset by margin compression and operating loss swing. However, management commentary indicates market recovery beginning in February with strong consumables unit volumes and optimistic forward guidance (10-15% Q2 growth, 16-25% full-year growth). The positive outlook and record unit volumes are balanced against current profitability challenges and declining gross margins.

The company reported year-over-year revenue growth of 3-4% in Q1 2026 ($9.6-$9.7 million), demonstrating continued business expansion. Additionally, the company previously announced record revenues for Q4 and full year 2025, indicating positive momentum in the business.

While revenues met guidance expectations with modest 3-4% growth, the company came in at the lower end of guidance due to deal delays from market headwinds in reimbursement. However, management expressed cautious optimism about market recovery and strong customer engagement, suggesting stabilization rather than deterioration. The mixed results and forward-looking optimism warrant a neutral stance.

Company achieved all-time record quarterly and annual revenues with strong 29.7% and 35% YoY growth respectively. UltraMist systems sales nearly doubled YoY (624 vs 374 units), consumables revenue grew 27.4%, and gross margins improved. Adjusted EBITDA increased significantly ($13.6M vs $7.2M). Forward guidance shows continued growth momentum of 16-25% for 2026. CEO commentary indicates favorable market positioning amid industry consolidation and CMS reimbursement changes.